GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes By Ogkologos - July 13, 2026 10 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large real-world cohort Source RELATED ARTICLESMORE FROM AUTHOR Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer MOST POPULAR Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant... June 18, 2021 EMA Recommends Extension of Indications for Avelumab December 17, 2020 All in the Family – A Story about Genetics and Breast... October 12, 2021 ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 Load more HOT NEWS Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and...
